Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: thioguanineDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT00022126
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธEmory University Hospital - Atlanta, Atlanta, Georgia, United States
๐บ๐ธLoma Linda University Medical Center, Loma Linda, California, United States
Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- University of California, Davis
- Registration Number
- NCT00009776
- Locations
- ๐บ๐ธ
University of California Davis Cancer Center, Sacramento, California, United States
Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 82
- Registration Number
- NCT00031824
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธAll Children's Hospital, St. Petersburg, Florida, United States
๐บ๐ธMaine Children's Cancer Program, Scarborough, Maine, United States
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 17
- Registration Number
- NCT00045305
- Locations
- ๐บ๐ธ
Jewish Hospital Cancer Center, Cincinnati, Ohio, United States
๐บ๐ธMayo Clinic - Jacksonville, Jacksonville, Florida, United States
๐บ๐ธMayo Clinic Scottsdale, Scottsdale, Arizona, United States
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
- Conditions
- Interventions
- Drug: Fludarabine PhosphateRadiation: Total-Body IrradiationProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Peripheral Blood Stem Cell TransplantationDrug: CyclosporineDrug: Mycophenolate MofetilBiological: Therapeutic Allogeneic LymphocytesOther: Laboratory Biomarker Analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00003145
- Locations
- ๐บ๐ธ
Baylor University Medical Center, Dallas, Texas, United States
๐บ๐ธFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
๐บ๐ธStanford University Hospitals and Clinics, Stanford, California, United States
Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020176
- Locations
- ๐บ๐ธ
NCI - Center for Cancer Research, Bethesda, Maryland, United States
๐บ๐ธWarren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT00044954
- Locations
- ๐บ๐ธ
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
๐บ๐ธUniversity of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
๐บ๐ธVanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, United States
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Childhood Myelodysplastic SyndromesChildhood Nasal Type Extranodal NK/T-cell LymphomaAcute Myeloid Leukemia/Transient Myeloproliferative DisorderAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in RemissionAcute Undifferentiated Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT00014235
- Locations
- ๐บ๐ธ
University of Arizona Health Sciences Center, Tucson, Arizona, United States
๐บ๐ธBaylor University Medical Center, Dallas, Texas, United States
๐บ๐ธOHSU Knight Cancer Institute, Portland, Oregon, United States
Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission
- Conditions
- Interventions
- Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationBiological: donor lymphocytesDrug: cyclosporineRadiation: total-body irradiationDrug: fludarabine phosphateDrug: mycophenolate mofetilOther: laboratory biomarker analysisProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-12-07
- Target Recruit Count
- 30
- Registration Number
- NCT00031655
- Locations
- ๐บ๐ธ
Veterans Affairs Puget Sound Healthcare System, Seattle, Washington, United States
๐บ๐ธFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
๐บ๐ธOregon Health and Sciences University, Portland, Oregon, United States
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-09-21
- Target Recruit Count
- 202
- Registration Number
- NCT00003838
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.